Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.59 |
| ▸ | KMO | O15229 | 2/20 | 0.53 |
| ▸ | ALPL | P05186 | 3/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.42 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29699481 | 0.86 | KMO (0.51) | SCN9AKMOALPLGRIN2BSLC1A5 | |
| SCHEMBL15384396 | 0.81 | KMO (0.50) | SCN9AKMO | |
| SCHEMBL6512836 | 0.80 | ALPL (0.46) | SCN9AKMOALPL | |
| SCHEMBL15943367 | 0.76 | AHR (0.48) | KMO | |
| SCHEMBL474418 | 0.76 | ALDH1A1 (0.53) | SCN9AKMO | |
| SCHEMBL14742275 | 0.75 | KMO (0.68) | KMOGRIN2B | |
| SCHEMBL4524262 | 0.75 | KMO (0.47) | SCN9AKMO | |
| SCHEMBL28155389 | 0.75 | SCN9A (0.52) | SCN9AALPL | |
| SCHEMBL22815581 | 0.75 | KMO (0.50) | SCN9AKMOGRIN2BSLC1A5 | |
| SCHEMBL28135481 | 0.75 | NOTUM (0.52) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | SCN9A 2941/4885KMO 248/4885ALPL 728/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | SCN9A 3323/4885KMO 255/4885ALPL 807/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | SCN9A 2941/4885KMO 248/4885ALPL 728/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | SCN9A 2941/4885KMO 248/4885ALPL 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.